Horizon Pharma Receives Two Additional Patents on Ravicti

Horizon Pharma Receives Two Additional Patents on Ravicti

Source: 
CP Wire
snippet: 

Horizon Pharma plc (Nasdaq:HZNP) announced on 5/8/18 that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/457,643 and 15/687,132, both entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs” that cover Horizon's U.S. approved medicine RAVICTI (glycerol phenylbutyrate) Oral Liquid.